Talphera (NASDAQ:TLPH – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03, Zacks reports.
Here are the key takeaways from Talphera’s conference call:
- Talphera said the NEPHRO CRRT study is progressing well, with enrollment now well above the 50% milestone and the company still expecting to complete enrollment in 2026.
- Management reiterated plans to file the PMA in 2026 and still targets a potential Niyad approval in 2027, saying the company is positioned for that timeline.
- The company said it does not plan additional enrollment updates before study completion; it expects to announce last patient out, then release top-line data within about a month afterward.
- Talphera ended the quarter with $21.1 million in cash and said that, along with future conditional tranches, should fund operations through at least a potential PMA approval next year.
- Cash operating expenses rose to $3.9 million from $2.9 million a year ago, driven mainly by higher Niyad development spending and some increased G&A costs.
Talphera Stock Performance
NASDAQ:TLPH traded up $0.04 during midday trading on Wednesday, reaching $0.90. The stock had a trading volume of 142,385 shares, compared to its average volume of 133,506. The firm has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $1.00. Talphera has a 12-month low of $0.38 and a 12-month high of $1.57.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on Talphera
Insider Activity
In related news, CEO Vincent J. Angotti bought 213,310 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were bought at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the transaction, the chief executive officer owned 800,705 shares of the company’s stock, valued at approximately $472,415.95. This trade represents a 36.31% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Badri N. Dasu bought 35,000 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were bought at an average price of $0.81 per share, for a total transaction of $28,350.00. Following the completion of the transaction, the insider directly owned 76,230 shares in the company, valued at approximately $61,746.30. This represents a 84.89% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 433,674 shares of company stock valued at $304,348. Corporate insiders own 3.50% of the company’s stock.
Institutional Investors Weigh In On Talphera
Institutional investors have recently made changes to their positions in the stock. Group One Trading LLC boosted its position in shares of Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after purchasing an additional 29,500 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Talphera during the 3rd quarter worth $29,000. Persistent Asset Partners Ltd purchased a new stake in shares of Talphera during the 4th quarter worth $42,000. Mariner LLC boosted its position in shares of Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after purchasing an additional 33,000 shares in the last quarter. Finally, Dauntless Investment Group LLC purchased a new stake in shares of Talphera during the 3rd quarter worth $89,000. 37.67% of the stock is currently owned by hedge funds and other institutional investors.
Talphera Company Profile
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
Read More
- Five stocks we like better than Talphera
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
